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Background: Gastrointestinal conditions are multifactorial in nature, and certain pa‐
tients can benefit greatly from brain–gut psychotherapies delivered by mental health 
professionals who specialize in psychogastroenterology. This study aimed to identify 
features associated with improvements in GI‐specific quality of life scores following 
behavioral health interventions (BHI). The second aim was to create a psychogastro‐
enterology referral care pathway incorporating identified characteristics for greatest 
benefit from GI‐specific behavioral therapy.
Methods: We performed a prospective observational study of 101 (63 women; median 
age,	45	years)	gastroenterology	patients	referred	for	psychogastroenterology	consulta‐
tion at a single center. Patients attended an average of seven sessions with a single GI 
psychologist where evidence‐based brain–gut psychotherapies were employed. GI‐spe‐
cific quality of life (IBS‐QOL) and psychological distress (BSI‐18) were assessed before 
and after BHI. Patients completed self‐reported questionnaires. We performed a multi‐
variable analysis to determine predictors associated with IBS‐QOL score improvement.
Key Results: A	 total	of	53	 (52.5%)	patients	experienced	 improvement	 in	 IBS‐QOL	
score. Patients with improved IBS‐QOL scores had significantly higher baseline BSI 
general domain T‐scores (61.9 vs. 56.9, P = 0.002). Female gender (odds ratio [OR], 
3.2),	pretreatment	BSI	somatization	T‐score	≥63	(OR,	3.7),	and	a	diagnosis	of	depres‐
sion	 (OR,	 4.2)	were	 associated	with	 greater	 odds	 of	 IBS‐QOL	 score	 improvement	
following BHI.
Conclusions and Inferences: We identified factors associated with response to GI‐
specific BHI to aid in optimizing the utilization of psychogastroenterology services 
and provide referring providers with information to inform treatment recommenda‐
tions. Female patients with disorders of gut–brain interaction (DGBIs), high somatiza‐
tion, and depression should be considered a priority for brain–gut psychotherapies.
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1  | INTRODUC TION
In patients with disorders of gut–brain interaction (DGBIs), comorbid 
depression	 and	 anxiety	 disorders	 occur	 in	 approximately	 30%	 and	
50%	of	patients,	 respectively.1 Crohn's disease and ulcerative colitis 
have a similar prevalence of mood disorders compared with those with 
DGBIs.2 Brain–gut psychotherapies are effective for improving quality 
of life and disease experience for a wide range of GI conditions tar‐
geting the multifactorial nature of DGBIs,3,4 upper GI conditions5 (eg, 
heartburn, dysphagia, and globus), and inflammatory bowel disease 
(IBD).2,6	As	a	result,	“psychogastroenterology”	has	organically	emerged	
as an effective treatment modality necessary for holistic GI care.7
At	 present,	 access	 to	 integrated	 psychogastroenterology	 pro‐
viders remains limited. While enthusiasm for referrals makes it clear 
that gastroenterologists and patients recognize the value of psy‐
chogastroenterology services, the patient phenotype most likely to 
benefit	from	these	services	has	not	been	fully	elucidated.	As	individ‐
ualized care pathways emerge and behavioral health is incorporated 
into treatment algorithms, both medical specialists and patients will 
benefit from clear guidance regarding the best psychologic resource 
to be used at a given time.
Analyses	were	performed	at	the	group	level	in	gastroenterology	
patients with DGBIs. We aimed to identify features associated with 
improvements in psychologic function and GI‐specific quality of life 
(QOL) using validated measures, as well as patient‐reported mental 
health improvements following behavioral health interventions.
2  | METHODS
2.1 | Study population
Patients seen in our university‐based outpatient gastroenterology 
clinic were referred for GI Behavioral Health Intervention (BHI) utiliz‐
ing our BHI referral criteria: patients with DGBIs, those lacking severe 
psychiatric comorbidity, those with insight into the role of stress on 
their GI functioning, and those motivated to address their GI symptoms 
using	brain–gut	psychotherapy.	Exclusion	criteria	were	untreated	mod‐
erate‐to‐severe psychiatric comorbidity and poor insight or motivation. 
Patients presented for the management of DGBIs; however, some pa‐
tients had a relevant co‐diagnosis of IBD, chronic pain conditions, and 
upper GI complaints. Referred patients were consecutively approached 
for participation in the study; those providing informed consent com‐
pleted validated questionnaires prior to and at the completion of BHI 
(Appendix	 S1).	 Patient	 self‐reported	 medical	 and	 prescription	 data	
were augmented and verified by review of electronic medical records.
2.2 | Measures
2.2.1 | Psychosocial checklist
Patients were asked to review a list of 36 current or past psycho‐
social stressors and identify which they have experienced. Key 
psychosocial stressors listed include the following: work problems, 
caregiver stress, difficulties with communication, loss of a loved one, 
anxiety, nightmares, sexual dysfunction, chronic pain, thoughts of 
self‐harm, abuse/trauma, eating disorder, and addiction.
2.2.2 | Demographic and clinical information
Patients provide their name, age, occupation, highest level of educa‐
tion completed, weight, height, and type of GI diagnosis.
2.2.3 | Concomitant treatment form
Patient is asked to list medical and/or psychiatric conditions and 
they currently have including psychiatric diagnoses and treat‐
ment history. Chronic pain conditions include chronic migraines 
or headaches, fibromyalgia, temporomandibular joint syndrome 
(TMJ),	 and	 interstitial	 cystitis	 (IC).	 The	use	of	psychoactive	pre‐
scription medications includes tricyclic antidepressants and 
atypical antipsychotic agents. Opioids, benzodiazepines, and illicit 
substance used for the 12 months preceding BHI referral were 
also collected.
2.2.4 | Rating of symptom severity
Patients self‐reported the severity of their last GI symptoms flare‐
up on a 10‐point Likert scale with higher scores indicating greater 
symptom severity.
2.2.5 | Irritable Bowel syndrome quality of life 
questionnaire (IBS‐QOL)
This	is	a	34‐item	self‐report	instrument	that	measures	health‐related	
QOL with eight symptom dimensions on a five‐point response scale: 
dysphoria, health worry, social reaction, interference with activity, 
sexual impact, body image, and relationships.8 Items are summed 
and averaged for a total score which is transformed to a 0‐100 scale 
Key Points
• Gastrointestinal conditions are multifactorial in nature, 
and certain patients can benefit greatly from brain–gut 
psychotherapies delivered by mental health profession‐
als who specialize in psychogastroenterology.
• Females with disorders of gut–brain interaction, high 
somatization, and depression should be considered pri‐
ority for brain–gut psychotherapies. Behavioral health 
outcomes were not limited to disease; patients with IBD 
should be routinely considered for referral.
• Optimizing utilization of GI‐specific behavioral health 
specialists for the best outcomes can maximize quality 
of life and disease experience, but also improve value‐
based care.
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with higher scores indicating better IBS‐specific QOL. Clinically, sig‐
nificant	QOL	improvement	is	defined	as	an	increase	of	14	or	more	
points.9
2.2.6 | Brief symptom inventory‐18 (BSI‐18)
Is an 18‐item reliable measure of general psychological distress in 
medical populations with four domains graded on a five‐point Likert 
scale including: somatization (the psychological tendency to experi‐
ence a multitude of non‐specific body symptoms), depression, anxi‐
ety, and Global Severity Index (GSI).10 Subscale scores range from 0 to 
72	and	are	converted	to	T‐scores.	A	BSI	T‐score	≥63,	which	is	greater	





health treatment is appropriate for their current medical complaints 
and to assess whether a psychiatric comorbidity takes precedence. 
Insight into the manner in which psychological factors can impact 
the GI symptom experience, in addition to patient's motivation to 
engage	in	BHI	was	assessed.	At	the	conclusion	of	the	interview,	ap‐
propriate patients were provided with a treatment plan with a target 
of seven sessions.
2.3 | Behavioral health intervention
Given that there is not a single standardized protocol for using CBT 
for gastrointestinal symptoms, our study consistently incorporated 
the application of CBT and gut‐directed hypnotherapy interventions 
which were appropriate for patients presenting complaints.3 Patient 
progress or willingness to proceed impacted the total number of 
sessions.
2.3.1 | Cognitive behavioral therapy (CBT)
This approach is routinely tailored to patients with GI conditions 
by providing psychoeducation about the body's stress response 
and how it can impact gastrointestinal functioning, address health‐
specific mood symptoms, improve coping skills and increase medi‐
cal adherence.4,6,12 Learning how to reduce physiological arousal 
and attenuate hypervigilance through the practice of relaxation 
skills (eg, diaphragmatic breathing, muscle relaxation, self‐hypno‐
sis) augments the patient's capability to maximally participate in 
CBT exercises.
2.3.2 | Gut‐directed hypnotherapy
This intervention has several evidence‐based benefits, specifically 
targeting the down‐regulation of unpleasant GI sensations by nor‐
malizing pain processing and perception via the brain–gut axis. It is 
successfully used in patients with functional abdominal and bowel 
complaints to improve health outcomes of visceral sensitivity, gut 
motility, central processing, and overall psychological status.13‐15 
This study used the North Carolina Protocol, a seven‐session 
scripted protocol designed for patients with IBS or IBD.13,16,17 In pa‐
tients with comorbid upper GI complaints, appropriate modifications 
were made utilizing tailored hypnotic suggestions.18
2.4 | Outcome assessment
Our primary outcome assessment was improved IBS‐QOL score 
post‐BHI.	 A	 clinically	 significant	 improvement	 in	 GI‐specific	 QOL	
was	defined	as	an	 increase	 in	 IBS‐QOL	score	≥14	points	post‐BHI	
treatment.9	At	termination	of	BHI	treatment,	participants	also	com‐
pleted BSI survey and self‐reported patient outcome measures 
including the following: perceived degree of improvement in GI 
symptom experience (excellent, moderate, slight, no improvement, 
and worse), reduction in on‐demand medication use for symptom 
relief and the use of BHI skills at the completion of therapy (CBT, 
diaphragmatic breathing, and self‐hypnosis).
2.5 | Statistical analysis
Demographic, clinical, and survey reply features prior to the start of 
BHI were compared between patients who experienced an improve‐
ment	in	IBS‐QOL	of	14	or	more	points	and	those	without	an	IBS‐QOL	
improvement. Univariate analysis was performed using student's t test, 
chi‐squared test, or Fisher's exact test in the setting of low‐frequency 
categorical	 events.	 Multivariable	 logistic	 regression	 model	 building	
utilized a backward variable selection process with forced inclusion of 
age, gender, and IBD deemed relevant a priori. Continuous variables 
were also explored as categorical variables (with and without ordinal 
features)	to	provide	the	best	model	fit.	Analysis	of	maximum	likelihood	
estimates provided hazard ratios and confidence limits for each pa‐
rameter within the model. Univariate analyses considered a P‐value of 
≤0.01	as	statistically	significant	after	applying	Bonferroni	correction	to	
control for Type 1 error due to multiple comparisons; regression analy‐





vation while undergoing BHI from 2015 to 2018. The overall popu‐
lation	was	62.4%	 female,	with	27.7%	having	comorbid	depression,	
42.6%	had	comorbid	anxiety,	22.8%	had	underlying	IBD,	and	22.8%	
had current psychotropic therapy use. The overall mean age was 
45.1	years	with	a	range	of	18.1‐80.4	years	of	age,	and	no	difference	
in age was observed by QOL score improvement. The population 
baseline	BSI	general	score	was	53.6	(SD	7.9),	and	baseline	IBS‐QOL	
score	was	54.0	(SD	16.5).	Fifty‐three	patients	(52.3%)	experienced	
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a clinically meaningful improvement in IBS‐QOL scores. Separating 
the overall study population by QOL improvement following BSI, 
positive predictors for clinically meaningful improvement in IBS‐
QOL scores were a higher baseline BSI score (P = 0.003) and the 
absence of upper tract symptoms (P	=	0.007,	Table	1).	Males	com‐
prised	 37.6%	of	 the	 cohort	 and	male	 vs	 female	 sex	 and	 exhibited	
a	 non‐significant	 trend	 of	 non‐response	 to	BHI	 (63.3%	 vs.	 38.1%,	
P = 0.018). The presence of upper tract GI symptom complaints oc‐
curred in 20 study subjects and was associated with non‐response 
to	BHI	(31.2%	vs.	9.4%,	P	=	0.007).21	of	101	patients	had	IBD,	10	
with Crohn's disease, and 11 with ulcerative colitis. The presence 
of IBD was not associated with achieving a clinically meaningful im‐
provement in IBS‐QOL scores (P	=	0.482).	Co‐existing	chronic	pain	
conditions were also not associated with responsiveness to BHI 
(P = 0.673).	Use	of	 psychoactive	medications,	 benzodiazepines,	 or	
opioids within the prior year was not associated with BHI response 
(P	=	0.714).	No	report	of	suicidal	ideation	and	formal	eating	disorder	
diagnoses occurred in this cohort.
3.2 | Pre‐BH intervention BSI scores and 
association with IBS‐QOL score improvement
Those with clinically meaningful improvements in IBS‐QOL scores 
had significantly higher baseline BSI general domain T‐scores (61.9 
vs. 56.9, P = 0.002). Higher pretreatment BSI somatization T‐scores 
(P	<	0.001)	were	associated	with	an	 improvement	 in	 IBS‐QOL	score	
(Table 2). Unsurprisingly, following BHI, anxiety (P = 0.015), depression 
(P = 0.005), and somatization (P	<	0.001)	BSI	subscores	all	 improved	
relative	to	baseline	values,	defined	as	a	T‐Score	≥63.
3.3 | Multivariable model for predicting QOL 
improvement following BH intervention
Adjusted	analysis	 identified	several	pretreatment	predictors	of	 IBS‐
QOL score improvement following BHI (Table 3). Females were more 
than three times as likely as males to experience clinically meaning‐
ful improvements in IBS‐QOL score. Those with a pretreatment BSI 
somatization T‐score of 63 or greater (upper quartile of the cohort) 
had	 a	 3.7‐fold	 greater	 odds	 of	 experiencing	 a	 clinically	meaningful	
TA B L E  1   Patient characteristics
 
Postintervention QOL Change
No improvement Improvement P
 n = 48 n = 53  
Age,	years	(SD) 47.4	(16.5) 42.9	(15.3) 0.181










9 (18.8) 13	(24.5) 0.482
Depression	(%) 8	(16.7) 20	(37.7) 0.018
Anxiety	(%) 20	(41.7) 23	(47.7) 0.578
Migraine	(%) 7	(14.6) 13	(24.5) 0.210
Fibromyalgia	(%) 6 (12.5) 9	(17.0) 0.527
Intersticial cysti‐
tis	(%)
7	(14.6) 8 (15.1) 0.943




5 (10.6) 6 (11.8) 0.860
Narcotic use Hx 
(%)
1 (2.1) 5 (9.8) 0.113
Psychotropic 
use	(%)





GI Sx severity 
rating (SD)
7.2	(1.6) 7.7	(1.6) 0.151






n = 48 n = 53
Value SD Value SD
BSI‐GSI PreTx score 
(Raw)
13.7 9.7 20.5 12.0 0.003
BSI‐GSI PreTx ZScore 57.0 8.5 61.9 8.7 0.006
BSI‐GSI PostTx score 53.3 8.1 53.3 7.9 0.966
BSI‐GSI Score change 3.4 7.1 8.6 7.4 0.001
BSI‐Dep PreTx score 
(Raw)
4.6 4.5 6.8 5.2 0.024
BSI‐Dep PreTx ZScore 54.9 9.6 59.4 9.8 0.023
BSI‐Dep PostTx score 51.9 8.5 51.0 8.4 0.605
BSI‐Dep Score change 57.0 8.5 61.9 8.7 0.006
BSI‐ANX	PreTx	score	
(Raw)
4.8 3.4 6.5 4.7 0.039
BSI‐ANX	PreTx	Zscore 55.1 9.0 58.2 9.9 0.102
BSI‐ANX	PostTx	score 51.6 7.4 51.1 7.5 0.741
BSI‐ANX	Score	
change
3.4 7.1 7.1 7.7 0.015
BSI‐SOM	PreTx	score	
(Raw)
4.4 3.4 7.2 4.7 0.001
BSI‐SOM	PreTx	
Zscore
56.8 9.0 62.5 9.3 0.003
BSI‐SOM	PostTx	score 53.5 9.0 55.1 8.2 0.349
BSI‐SOM	Score	
change
3.2 7.6 7.5 7.5 0.005
Abbreviations:	ANX:	Anxiety	Subscore;	DEP:	Depression	subscore;	GSI:	
General	Severity	Index;	SOM:	Somatization	subscore.
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improvement in IBS‐QOL score following BHI. Those with a pretreat‐
ment BSI general score of 63 or greater also had greater odds of suc‐
cessful	 response	 to	BHI	 (OR	2.3,	95%	CI	1.2,	4.1),	but	 this	was	not	
retained in the final model due to co‐linearity with the BSI‐somati‐
zation.	A	diagnosis	of	depression	(OR	4.20,	95%	CI	1.22,	14.47)	but	
not anxiety was associated with greater odds of meaningful IBS‐QOL 
score improvement following BHI. Psychoactive medication, narcotic, 
nor benzodiazepine were risk factors for failure of BHI. The diagnosis 
of IBD (P	=	0.942)	or	chronic	pain	conditions	(P = 0.869) was not risk 
factors for BHI failure. Finally, the presence of upper tract symptoms 
(which could co‐occur with lower tract symptom complaints) signifi‐
cantly reduced the odds of experiencing a meaningful improvement 
in	IBS‐QOL	score	(OR	0.15,	95%	CI	0.04,	0.59)	on	adjusted	analysis.
3.4 | Patient‐reported improvements and self‐
directed use of behavioral health techniques
The vast majority of patients reported continued use of behavioral 
health	skills,	with	91%	indicating	continued	diaphragmatic	breathing	
use	and	96%	reporting	continued	CBT	skill	set	use	at	the	completion	
of their therapy course. Those patients who had an improved IBS‐QOL 
score reported reduced use of on‐demand medications for GI symp‐
tom	relief	(66.0%	vs.	34.0%,	P = 0.007).	Additionally,	subjective	patient	
self‐report of improvement following BHI demonstrated poor agree‐
ment	with	objective	IBS‐QOL	scores	(=0.26).	Overall,	of	the	45/101	
patients self‐reporting moderate or better improvement following 
BHI,	only	37.8%	(17/45)	demonstrated	a	14	point	or	greater	improve‐
ment on the IBS‐QOL instrument (P = 0.008) (Figure 1).
4  | DISCUSSION
In summary, we identify several factors associated with GI behavio‐
ral health interventions that successfully improve GI‐specific QOL 
scores. Female patients with high somatization scores appear to 
have the most potential for improvement following BHI for FGIDs. 
Alternatively,	male	patients	and	those	presenting	with	co‐occurring	
upper GI tract functional symptoms appear to be less responsive to 
BHI. Finally, a co‐diagnosis of IBD, a history of opioid, benzodiaz‐
epine, or psychoactive medication use does not appear to impact 
success of BHI. Understanding these features may help providers en‐
courage patients with a high probability of response to undergo BHI.
The reasons for difference in gender response to BHI remain 
unclear and could be linked to fundamental aspects of bowel symp‐
tom experience that are uncaptured by existing measures of ther‐
apeutic response and QOL. Further evidence of shortcomings in 
understanding treatment response may be linked to limitations in 
how we measure response. In our study, despite the IBS‐QOL being 
an established measure, a bidirectional discrepancy was present 
between patients’ subjective perception of improvement and their 
IBS‐QOL score improvement. This suggests that patient perceptions 
of QOL and therapeutic benefit, at least in the context of GI BHI, 
are impacted by unmeasured variables. One consideration of this 
discrepancy is that some patients consciously or unconsciously may 
have been skewed toward more positive responses given they were 
returning treatment completion forms to the office of the single pro‐
vider. While a limitation, it is a reality of this objective study.
Prior work has demonstrated that upper GI tract digestive com‐
plaints are more resistant to BHI.5,19 While our analysis found them 
less likely to respond to BHI, this indicates comorbid bowel and 
esophageal complaints likely require more intensive therapy and 
further customized BHI regimens.
Not surprisingly, patients reporting clinically significant soma‐
tization were found to be highly successful in behavioral therapy. 
We must also acknowledge that in a GI patient population, the BSI 
somatization score may be a measure of GI symptom severity; there‐
fore, we may anticipate those patients with the worst GI symptoms 
at baseline and may be more likely to respond to BHI. This supports 
previous reports where hypnotherapy was superior to other inter‐
vention for reducing bothersome non‐GI symptoms in DGBIs.20‐22
These results should be interpreted in the context of several lim‐
itations. Firstly, we used the IBS‐QOL, which is a QOL measurement 
tool validated in IBS patients, as our primary measure of improve‐
ment of DGBIs following BHI. This tool has not been validated in IBD 
or upper tract symptoms, and as such, the instrument conceivably 
may perform differently in patients with non‐IBS diagnoses. While 
we acknowledge a lack of patient characterization, all referred pa‐
tients had functional bowel complaints as the primary reason for re‐
ferral and we elected to use a single instrument to minimize patient 




Age 0.98 0.95 1.01 0.183
Gender, Female 3.25 1.13 9.35 0.029
BSI	SOM	>63 3.74 1.19 11.72 0.024
Diagnosis major depression 4.20 1.22 14.47 0.023
Diagnosis anxiety disorder 0.37 0.11 1.18 0.092
Absence	of	upper	GI	functional	
symptoms
6.48 1.70 24.74 0.006
IBD co‐diagnosis 0.96 0.31 3.00 0.942
Bold indicates significant values. 
TA B L E  3  Multivariable	model	of	
achieving quality of life improvement 
following behavioral health intervention
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hypnotherapy and CBT interventions, the lack of standardized treat‐
ment for every patient introduced an uncontrolled variable that this 
study was not designed to evaluate and should be part of future con‐
trolled interventional studies. Further, therapy was administered by 
a single GI behavioral health psychologist whose individual charac‐
teristics administrating care could influence results. However, this 
limitation also underscores the importance of training GI psychol‐
ogists as there is a current shortage of available providers. Finally, 
over the course of the study, referring gastroenterologists’ likely im‐
proved their patient selection for BHI referral as they received both 
psychologist and patient feedback. While potentially impacting re‐
sults, if gastroenterologist referral pattern changes improved overall 
patients’ BHI success, this would demonstrate the potential for im‐
proving patient selection practices. While the limitations highlighted 
preclude a conclusion of BHI effectiveness for improving functional 
bowel symptoms in patients with important co‐diagnoses, the re‐
sults support investment in more rigorous studies.
Our findings are consistent with other investigations of behav‐
ioral health utilization in gastroenterology. We propose a preliminary 
schema to aid gastroenterology providers in identifying patients for 
BHIs with a higher likelihood of symptomatic response and IBS‐QOL 
score improvements (Figure 2) . Referring patients with the most to 
gain from BHIs may not only maximize population‐level improve‐
ments in QOL and disease experience but additionally could increase 
the overall value of outpatient gastroenterology services.
Finally, in the case of patients with IBD, functional complaints 
have been associated with higher healthcare utilization and costs.23 
Psychiatric comorbidity has also been associated with hospital re‐
admissions and unnecessary, costly diagnostic testing in this pop‐
ulation.24,25 We found that behavioral health outcomes were not 
limited to disease, and therefore, it is important to consider patients 
with IBD for brain–gut psychotherapies despite limited research.6
Recognizing the positive impact on many digestive diseases, 
both gastroenterologists and patients are increasingly seeking 
F I G U R E  1   Patient quality of life 
improvement following behavioral health 
intervention
F I G U R E  2   Proposed referral guide for 
mental and behavioral health services in 
patients with gastrointestinal conditions. 
The above schema incorporates 
predictors of improvement of quality 
of life in patients with gastrointestinal 
complaints following behavioral health 
interventions, as well as experience‐based 
suggestions for most beneficial first 
mental health provider. Complex patients 
are encouraged to establish care with 
general mental health care OR establish 
comprehensive psychiatric care to 
stabilize mood. They may then present for 
re‐assessment with a GI psychologist after 
6 months of stable mood and treatment
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psychogastroenterology services. Incorporation of a validated com‐
plexity measure would be helpful in further developing a risk stratifi‐
cation model for the dissemination of GI behavioral health services. 
Future work will be aimed at evaluating economic factors such as 
changes in healthcare utilization and cost‐effectiveness analyses 
when a more select group of GI patients are prioritized for behavioral 
health care. With improved pathways to care, our capacity to provide 
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